Mrs Magdalena Kovac, MD in Navarre, OH - General Practice

Mrs Magdalena Kovac, MD is a General Practice physician based in Navarre, Ohio. Mrs Magdalena Kovac is licensed to practice in Ohio (license number 35039368) and her current practice location is 24 Cecil St Ne, Navarre, Ohio. She can be reached at her office (for appointments etc.) via phone at (330) 879-2243.

NPI number for Mrs Magdalena Kovac is 1578633293 and her current mailing address is 9058 Lawndell Sw, Navarre, Ohio. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1578633293.

Contact Information

	Mrs Magdalena Kovac, MD
	24 Cecil St Ne, Navarre, OH 44662
	(330) 879-2243
	(330) 879-2243

Physician's Profile

Full Name	Mrs Magdalena Kovac
Gender	Female
Speciality	General Practice
Location	24 Cecil St Ne, Navarre, Ohio
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1578633293
Provider Enumeration Date: 11/09/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mrs Magdalena Kovac such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1578633293	NPI	-	NPPES
0338334	Medicaid	OH

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	35039368 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Magdalena Kovac is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Magdalena Kovac, MD 9058 Lawndell Sw, Navarre, OH 44662 Ph: (330) 879-5555	Mrs Magdalena Kovac, MD 24 Cecil St Ne, Navarre, OH 44662 Ph: (330) 879-2243

News Archive

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

Sugar-based stent makes precarious sewing process easier

Reconstructive procedures and organ transplants demand nimble fingers that can restore blood flow by stitching together millimeter-scale arteries. It's a tough ask and time-consuming task for even the most skilled surgeon.

Women with PCOS may be more vulnerable to BPA exposure: Study

Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

2009 IOF-AMGEN Health Professional Awareness Grants aim to raise osteoporosis awareness

Presented today at the International Osteoporosis Foundation's (IOF) Worldwide Conference of Osteoporosis Patient Societies in Beijing, the 2009 IOF-AMGEN Health Professional Awareness Grants aim to support innovative and cost effective projects by IOF member societies that focus on improving knowledge and raising awareness of osteoporosis among clinicians and allied health professionals.

Mrs Magdalena Kovac, MD - General Practice in Navarre, OH